By Josh White
Date: Wednesday 08 Jul 2026
(Sharecast News) - Avacta Therapeutics said on Wednesday it had appointed healthcare executive Patrick Vink to its board as non-executive deputy chairman and senior independent director.
By Josh White
Date: Thursday 25 Jun 2026
(Sharecast News) - Avacta said on Thursday it had agreed the design of a pivotal US trial for its lead cancer therapy with the US Food and Drug Administration, while reporting further clinical data that it said strengthened the case for its preCISION oncology platform.
By Josh White
Date: Monday 22 Jun 2026
(Sharecast News) - Avacta Therapeutics said on Monday that it had made strong progress across its oncology pipeline in the first half of 2026, including the start of clinical work for its second-generation preCISION drug candidate AVA6103.
| Currency | UK Pounds |
| Share Price | 68.80p |
| Change Today | 0.80p |
| % Change | 1.18 % |
| 52 Week High | 89.50 |
| 52 Week Low | 49.00 |
| Volume | 736,005 |
| Shares Issued | 471.33m |
| Market Cap | £324.28m |
| Beta | 0.01 |
| RiskGrade | 461 |
| Value |
|
|---|
| Price Trend |
|
|---|
| Income | ![]() |
|---|
| Growth |
|
|---|
| Strong Buy | 2 |
| Buy | 0 |
| Neutral | 1 |
| Sell | 0 |
| Strong Sell | 0 |
| Total | 3 |

| No dividends found |
| Time | Volume / Share Price |
| 17:07 | 5,000 @ 68.80p |
| 16:35 | 18,273 @ 68.80p |
| 16:35 | 213 @ 68.80p |
| 16:35 | 2,560 @ 68.80p |
| 16:35 | 3,000 @ 68.80p |
| CEO | Christina Coughlin |
| CFO | Brian Hahn |
You are here: research